download.png
CORXEL Acquires Worldwide (excluding Greater China) Rights to an Oral Small Molecule GLP-1 RA for the Treatment of Obesity and Diabetes
23 déc. 2024 08h01 HE | Corxel Pharmaceuticals
CORXEL expands its cardiometabolic pipeline into obesity and diabetes.